The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
The full article is available to subscribers Subscriber Login   

The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate (Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. Cotempla XR-ODT is the first extended-release orally disintegrating tablet formulation of methylphenidate to become available in the US.

METHYLPHENIDATE — Long-acting methylphenidate formulations are the mainstay of clinical practice for treatment of ADHD, but some of these products are available only as tablets or capsules that children may find difficult to swallow. Capsules can be opened and their contents sprinkled on applesauce. Other formulations of extended-release methylphenidate that can be used for children who are unable to swallow a pill include a chewable tablet, an oral suspension, and a transdermal patch, but none of these are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
Article code: 1533d
 Electronic, downloadable article - $25